Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.57 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.52 |
| ▸ | GRK2 | P25098 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | ESRRG | P62508 | 1/20 | 0.42 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4886692 | 0.92 | SRC (0.51) | SRCROCK2ROCK1GRK2MMP13 | |
| SCHEMBL4897239 | 0.92 | SRC (0.55) | SRCROCK2ROCK1GRK2MMP13 | |
| SCHEMBL4899070 | 0.90 | MAOB (0.51) | SRCROCK2ROCK1MAOB | |
| SCHEMBL4890357 | 0.88 | SRC (0.47) | SRCROCK2ROCK1GRK2MMP13 | |
| SCHEMBL4899116 | 0.88 | SRC (0.48) | SRCROCK2ROCK1GRK2DGAT2 | |
| SCHEMBL4899110 | 0.87 | HDAC1 (0.44) | SRCROCK2GRK2DGAT2ESRRG | |
| SCHEMBL4899454 | 0.87 | SRC (0.56) | SRCROCK2ROCK1MMP13DGAT2 | |
| SCHEMBL4895983 | 0.86 | SRC (0.50) | SRCROCK2ROCK1MMP13MAOB | |
| SCHEMBL4891551 | 0.86 | SRC (0.50) | SRCROCK2ROCK1MMP13DGAT2 | |
| SCHEMBL4888626 | 0.84 | MAOB (0.50) | SRCROCK2ROCK1MMP13MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815924-B2 | Heterocyclic carbonyl compounds | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | claimed |
| US-20080090882-A1 | Inhibitors of kinase h-sgk (human serum and glucocorticoid dependent kinase or SGK); diabetes, obesity, metabolic syndrome, systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, fibroses and inflammatory processes; amide-substituted imidazoles, oxazoles, thiazoles, or furans | MERCK PATENT GMBH (DE) | 2008-04-17 | — | — | US | claimed |
| US-8815924-B2 | Heterocyclic carbonyl compounds | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-8815924-B2 | Heterocyclic carbonyl compounds | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-20080090882-A1 | Inhibitors of kinase h-sgk (human serum and glucocorticoid dependent kinase or SGK); diabetes, obesity, metabolic syndrome, systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, fibroses and inflammatory processes; amide-substituted imidazoles, oxazoles, thiazoles, or furans | MERCK PATENT GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
| US-20080090882-A1 | Inhibitors of kinase h-sgk (human serum and glucocorticoid dependent kinase or SGK); diabetes, obesity, metabolic syndrome, systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, fibroses and inflammatory processes; amide-substituted imidazoles, oxazoles, thiazoles, or furans | MERCK PATENT GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
| US-20080090882-A1 | Inhibitors of kinase h-sgk (human serum and glucocorticoid dependent kinase or SGK); diabetes, obesity, metabolic syndrome, systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, fibroses and inflammatory processes; amide-substituted imidazoles, oxazoles, thiazoles, or furans | MERCK PATENT GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090882-A1 | Inhibitors of kinase h-sgk (human serum and glucocorticoid dependent kinase or SGK); diabetes, obesity, metabolic syndrome, systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, fibroses and inflammatory processes; amide-substituted imidazoles, oxazoles, thiazoles, or furans | SGK1, SGK2, SGK3 | SRC 334/4885ROCK2 1337/4885ROCK1 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.